Real-World Evidence (RWE) can include data from sources such as electronic health records (EHRs), insurance claims and billing activities, patient registries, patient-generated data, and data gathered from other sources that reflect the patient’s health status. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), inspect RWE studies to ensure that they’re conducted to the highest standards of scientific integrity, validity, and reliability.
 
Here are some key aspects that are usually inspected in the context of regulatory authority inspections:
 
[1] Data Quality and Integrity: Regulatory authorities review the systems and processes in place to ensure data accuracy, completeness, and consistency. This can include reviewing data collection methods, data management systems, and any algorithms used to process or analyse the data.
 
[2] Methodology: The design and conduct of RWE studies are critically reviewed. This includes the study protocol, statistical analysis plan, and any modifications made during the study. The methodology should be clear, robust, and scientifically sound to generate reliable evidence. Where consideration of a scientific standard or best practice is recommended (e.g., ISPE GPP) and not followed, this should be justified.
 
[3] Regulatory Compliance: While RWE (observational) studies may not fall under the GCP umbrella, ethical conduct, patient privacy, and data protection are still paramount. Compliance with laws like HIPAA in the United States or GDPR in the European Union, is essential, as is compliance with the local laws that govern RWE studies.
 
To prepare for a regulatory authority inspection, consider the following steps:
 
[1] Ensure data quality: Maintain rigorous data management practices. Make sure your data is accurate, complete, and auditable.
 
[2] Document everything: Keep comprehensive records of all activities related to the study. This includes detailed protocols, data collection methods, data handling procedures, and analysis plans. Also, document any changes made during the study and the reasons for those changes.
 
[3] Protect patient privacy: Ensure that your data management systems meet the required standards for protecting patient privacy. Anonymize data whenever possible and follow all relevant data protection laws.
 
[4] Prepare a team: Have a team that’s familiar with the study and prepared to answer questions from inspectors. This team should be knowledgeable about the study design, data management, and analysis.
 
[5] Conduct internal audits: Regular internal audits can help identify potential issues before an inspection. They can also provide opportunities to improve your procedures and systems.
 
Remember, each regulatory authority may have its own specific requirements, so it’s essential to understand and comply with the regulations of the jurisdiction in which you’re operating.